Industrial manufacturing company Ingersoll Rand (NYSE: IR) met Wall Streets revenue expectations in Q3 CY2025, with sales up 5.1% year on year to $1.96 billion. Its non-GAAP profit of $0.86 per share was in line with analysts’ consensus estimates.

Is now the time to buy IR? Find out in our full research report (it’s free for active Edge members).

StockStory’s Take

Ingersoll Rand’s third quarter was met with a significant negative market reaction, as the company’s revenue and non-GAAP earnings per share matched Wall Street expectations, but underlying challenges began to surface. Management attributed the quarter’s results to persistent headwinds from recently implemented tariffs, slower organic growth across core industrial end markets, and delayed realization of pricing actions. CEO Vicente Reynal remarked that "the current dynamic tariff environment" is a temporary margin headwind, while CFO Vikram Kini highlighted proactive cost measures and disciplined M&A as key responses to these pressures.

Looking ahead, Ingersoll Rand’s revised guidance reflects continued caution, with management emphasizing the impact of tariffs and the timing of price realization as central challenges. Reynal stated that tariff-related costs will continue to weigh on margins into the first half of next year, but expects pricing actions to gradually offset these pressures. Kini further indicated that cost optimization initiatives and ongoing backlog growth should position the company to recover margin expansion in the second half of the year, while maintaining a focus on bolt-on acquisitions to drive long-term growth.

Key Insights from Management’s Remarks

Management pointed to tariff-related costs, backlog-driven pricing delays, and steady execution on M&A as the main themes shaping the quarter’s performance and guidance revisions.

• Tariff impact on margins: Tariff increases, particularly Section 232 tariffs, were described as the single largest drag on margins this quarter. Management expects these to continue impacting results until pricing adjustments fully flow through the backlog.
• Backlog delays pricing benefits: The company’s growing backlog delayed the realization of recent price increases, with CFO Vikram Kini noting that most pricing actions will not be reflected in revenue until next year, especially for longer-cycle projects.
• Disciplined M&A activity: Ingersoll Rand closed 14 bolt-on acquisitions year-to-date, targeting businesses that enhance its technological capabilities and life sciences footprint, with CEO Reynal highlighting the recent addition of Dave Barry Plastics to the Life Science platform.
• Segment dynamics: The Precision and Science Technologies (PST) segment saw strong margin expansion and order growth, particularly in life sciences and short-cycle industrial businesses, while the Industrial Technologies and Services (ITS) segment faced revenue headwinds from tough clean energy project comparisons in the U.S.
• Cost structure optimization: Proactive headcount reduction and other cost actions were implemented to offset margin pressures, but their full impact is not expected until 2026, indicating a lag between cost measures and financial improvement.

Drivers of Future Performance

Ingersoll Rand’s outlook is shaped by the ongoing effects of tariffs, delayed pricing realization, and continued investment in M&A and cost optimization.

• Tariff headwinds and pricing lag: Management expects tariffs to suppress margins into the first half of next year, with price increases already implemented but not fully realized in revenue due to backlog timing. CFO Kini described this as a "wraparound impact" that should normalize by the second half of 2026.
• Cost optimization measures: Recent restructuring actions, focused mainly on headcount, are anticipated to deliver financial benefits in 2026. Management views these actions as prudent responses to a dynamic cost environment and expects a one-year payback period.
• M&A as a growth lever: The company is maintaining its strategy of frequent bolt-on acquisitions to drive above-market growth, particularly in life sciences and biopharma. CEO Reynal indicated that larger deals may be considered every few years, but the immediate focus remains on smaller, high-return opportunities.

Catalysts in Upcoming Quarters

In the coming quarters, the StockStory team will focus on (1) evidence that price increases are being realized in reported revenue as backlog unwinds, (2) the effectiveness of cost optimization efforts in supporting margin recovery, and (3) ongoing strength in the PST segment, especially in life sciences and medical markets. Progress on bolt-on acquisitions and any changes to the tariff regime will also be closely monitored as potential inflection points.

Ingersoll Rand currently trades at $76.33, down from $78.68 just before the earnings. Is the company at an inflection point that warrants a buy or sell? The answer lies in our full research report (it’s free for active Edge members).

Stocks That Trumped Tariffs

Trump’s April 2025 tariff bombshell triggered a massive market selloff, but stocks have since staged an impressive recovery, leaving those who panic sold on the sidelines.

Take advantage of the rebound by checking out our Top 5 Strong Momentum Stocks for this week. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025).

Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-micro-cap company Kadant (+351% five-year return). Find your next big winner with StockStory today.

StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here.